Premium
Metformin and the risk of head and neck cancer: a case–control analysis
Author(s) -
Becker C.,
Jick S. S.,
Meier C. R.,
Bodmer M.
Publication year - 2014
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.12351
Subject(s) - medicine , metformin , odds ratio , body mass index , confidence interval , diabetes mellitus , confounding , case control study , population , cancer , medical prescription , insulin , endocrinology , environmental health , pharmacology
Aims Metformin use has been associated with a decreased risk of some cancers, although data on head and neck cancer (HNC) are scarce. We explored the relation between the use of antidiabetic drugs and the risk of HNC. Methods We conducted a case–control analysis in the UK‐based Clinical Practice Research Datalink (CPRD) of people with incident HNC between 1995 and 2013 below the age of 90 years. Six controls per case were matched on age, sex, calendar time, general practice and number of years of active history in the CPRD prior to the index date. Other potential confounders including body mass index (BMI), smoking, alcohol consumption and comorbidities were also evaluated. The final analyses were adjusted for BMI, smoking and diabetes mellitus (or diabetes duration in a sensitivity analysis). Results are presented as odds ratios (ORs) with 95% confidence intervals (CIs). Results Use of metformin was neither associated with a statistically significant altered risk of HNC overall (1–29 prescriptions: adjusted OR 0.87, 95% CI 0.61–1.24 and ≥30 prescriptions adjusted OR 0.80, 95% CI 0.53–1.22), nor was long‐term use of sulphonylureas (adjusted OR 0.87, 95% CI 0.59–1.30), or any insulin use (adjusted OR 0.92, 95% CI 0.63–1.35). However, we found a (statistically non‐significant) decreased risk of laryngeal cancer associated with long‐term metformin use (adjusted OR 0.41, 95% CI 0.17–1.03). Conclusions In this population‐based study, the use of antidiabetic drugs was not associated with a materially altered risk of HNC. Our data suggest a protective effect of long‐term metformin use for laryngeal cancer.